OTCMKTS:ISCO International Stem Cell (ISCO) Stock Price, News & Analysis $0.33 +0.01 (+1.54%) As of 01:20 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsSEC Filings About International Stem Cell Stock (OTCMKTS:ISCO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ISCO alerts:Sign Up Key Stats Today's Range$0.30▼$0.3350-Day Range$0.17▼$0.5152-Week Range$0.12▼$0.54Volume3,144 shsAverage Volume19,582 shsMarket Capitalization$2.64 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview International Stem Cell Corporation is a biotechnology company focused on developing human stem cell-based products and therapies. Its research has centered on proprietary parthenogenetic human stem cells, which are derived from unfertilized human oocytes and are intended to provide a potentially useful source of cells for regenerative medicine. The company has pursued applications in tissue engineering and cell therapy, including programs involving corneal tissue and other specialized cell types. Its development activities have included research into producing differentiated cells from parthenogenetic stem cells for potential use in treating disease and repairing damaged tissue. International Stem Cell has also operated through subsidiaries and related businesses involved in commercial skincare products. Its Lifeline Skin Care business markets products incorporating human stem cell-derived ingredients, extending the company’s activities beyond therapeutic research into the consumer skincare market.AI Generated. May Contain Errors. Read More International Stem Cell Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks25th Percentile Overall ScoreISCO MarketRank™: International Stem Cell scored higher than 25% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for International Stem Cell. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of International Stem Cell is -4.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of International Stem Cell is -4.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the float of International Stem Cell has been sold short.Short Interest Ratio / Days to CoverInternational Stem Cell has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in International Stem Cell has recently decreased by 94.06%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInternational Stem Cell does not currently pay a dividend.Dividend GrowthInternational Stem Cell does not have a long track record of dividend growth. News and Social Media3.1 / 5News SentimentN/A News SentimentInternational Stem Cell has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for International Stem Cell this week, compared to 0 articles on an average week. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, International Stem Cell insiders have not sold or bought any company stock.Percentage Held by Insiders78.05% of the stock of International Stem Cell is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsInternational Stem Cell has minimal institutional ownership at this time.Read more about International Stem Cell's insider trading history. Receive ISCO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for International Stem Cell and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ISCO Stock News HeadlinesISCO - International Stem Cell CorporationSeptember 18, 2026 | seekingalpha.comInternational Stem Cell (OTCMKTS:ISCO) Stock Price Passes Above 200-Day Moving Average - Here's WhySeptember 18, 2026 | americanbankingnews.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.September 29 at 1:00 AM | Banyan Hill Publishing (Ad)Der aktuelle Kurs der International Stem Cell Corp Aktie beträgt 0,490.August 27, 2026 | de.investing.comما هو سعر سهم International Stem Cell (ISCO) اليوم؟August 22, 2026 | sa.investing.comSpaceflight accelerates the aging of human blood-forming stem cellsSeptember 9, 2025 | yahoo.comStem Cell Therapy Begins to Emerge as Potential IBD TreatmentJuly 15, 2025 | msn.comSee photos from final round of 2025 PGA Tour ISCO ChampionshipJuly 15, 2025 | msn.comSee More Headlines ISCO Stock Analysis - Frequently Asked Questions How have ISCO shares performed this year? International Stem Cell's stock was trading at $0.14 at the start of the year. Since then, ISCO shares have increased by 135.7% and is now trading at $0.33. How were International Stem Cell's earnings last quarter? International Stem Cell Corp. (OTCMKTS:ISCO) issued its quarterly earnings data on Thursday, August, 13th. The biotechnology company reported ($0.01) earnings per share for the quarter. The biotechnology company earned $2.67 million during the quarter. How do I buy shares of International Stem Cell? Shares of ISCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of International Stem Cell own? Based on aggregate information from My MarketBeat watchlists, some other companies that International Stem Cell investors own include Canopy Growth (CGC), Aurora Cannabis (ACB), Amarantus Bioscience (AMBS), Fulcrum Therapeutics (FULC), Kutcho Copper (KCCFF), B2Gold (BTG) and Cannabis Wheaton Income (CBWTF). Company Calendar Last Earnings8/13/2026Today9/29/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:ISCO CIK1355790 Webwww.internationalstemcell.com Phone(760) 940-6383Fax760-476-0600Employees33Year Founded2001Profitability EPS (Trailing Twelve Months)($0.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$420 thousand Net Margins-6.12% Pretax Margin-6.12% Return on EquityN/A Return on Assets-11.47% Debt Debt-to-Equity RatioN/A Current Ratio0.79 Quick Ratio0.45 Sales & Book Value Annual Sales$9.10 million Price / Sales0.29 Cash FlowN/A Price / Cash FlowN/A Book Value($0.51) per share Price / Book-0.65Miscellaneous Outstanding Shares8,004,000Free Float1,757,000Market Cap$2.64 million OptionableNot Optionable BetaN/A Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (OTCMKTS:ISCO) was last updated on 9/29/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding International Stem Cell Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share International Stem Cell With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
